Enhancing the therapeutic potential of peptide toxins

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Introduction: Peptide toxins are potent and often exquisitely selective probes of the structure and function of ion channels and receptors, and as such are of significant interest to the pharmaceutical and biotech industries as both therapeutic leads and pharmacological tools. Their progression as clinical candidates, however, faces many of the challenges that are common to peptide drugs generally. 

Areas covered: The attributes of peptide toxins as therapeutic leads are outlined, as well as some of the limiting factors that have hampered the clinical development of many promising candidates. Strategies to overcome or circumvent these limitations are described, and their applications to peptide toxins from cone snails, sea anemones and scorpions are exemplified. 

Expert opinion: Peptide toxins have exceeded their promise as valuable pharmacological tools but have yet to yield the anticipated bounty of therapeutic leads. As the number of new peptides identified in venom transcriptomes and proteomes expands rapidly, screening approaches that capture those with genuine therapeutic potential are required, along with methods for enhancing the stability, pharmacokinetics and pharmacodynamics of these peptides.

Original languageEnglish
Pages (from-to)611-623
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume12
Issue number6
DOIs
Publication statusPublished - 3 Jun 2017

Keywords

  • Cone snail
  • cyclisation
  • delivery
  • disulfide
  • PEGylation
  • pharmacodynamics
  • pharmacokinetics
  • proteolysis
  • scorpion
  • sea anemone

Cite this

@article{a45e24d76382499fa81d22425868f9e3,
title = "Enhancing the therapeutic potential of peptide toxins",
abstract = "Introduction: Peptide toxins are potent and often exquisitely selective probes of the structure and function of ion channels and receptors, and as such are of significant interest to the pharmaceutical and biotech industries as both therapeutic leads and pharmacological tools. Their progression as clinical candidates, however, faces many of the challenges that are common to peptide drugs generally. Areas covered: The attributes of peptide toxins as therapeutic leads are outlined, as well as some of the limiting factors that have hampered the clinical development of many promising candidates. Strategies to overcome or circumvent these limitations are described, and their applications to peptide toxins from cone snails, sea anemones and scorpions are exemplified. Expert opinion: Peptide toxins have exceeded their promise as valuable pharmacological tools but have yet to yield the anticipated bounty of therapeutic leads. As the number of new peptides identified in venom transcriptomes and proteomes expands rapidly, screening approaches that capture those with genuine therapeutic potential are required, along with methods for enhancing the stability, pharmacokinetics and pharmacodynamics of these peptides.",
keywords = "Cone snail, cyclisation, delivery, disulfide, PEGylation, pharmacodynamics, pharmacokinetics, proteolysis, scorpion, sea anemone",
author = "Norton, {Raymond S.}",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/17460441.2017.1317243",
language = "English",
volume = "12",
pages = "611--623",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Taylor & Francis",
number = "6",

}

Enhancing the therapeutic potential of peptide toxins. / Norton, Raymond S.

In: Expert Opinion on Drug Discovery, Vol. 12, No. 6, 03.06.2017, p. 611-623.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Enhancing the therapeutic potential of peptide toxins

AU - Norton, Raymond S.

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Introduction: Peptide toxins are potent and often exquisitely selective probes of the structure and function of ion channels and receptors, and as such are of significant interest to the pharmaceutical and biotech industries as both therapeutic leads and pharmacological tools. Their progression as clinical candidates, however, faces many of the challenges that are common to peptide drugs generally. Areas covered: The attributes of peptide toxins as therapeutic leads are outlined, as well as some of the limiting factors that have hampered the clinical development of many promising candidates. Strategies to overcome or circumvent these limitations are described, and their applications to peptide toxins from cone snails, sea anemones and scorpions are exemplified. Expert opinion: Peptide toxins have exceeded their promise as valuable pharmacological tools but have yet to yield the anticipated bounty of therapeutic leads. As the number of new peptides identified in venom transcriptomes and proteomes expands rapidly, screening approaches that capture those with genuine therapeutic potential are required, along with methods for enhancing the stability, pharmacokinetics and pharmacodynamics of these peptides.

AB - Introduction: Peptide toxins are potent and often exquisitely selective probes of the structure and function of ion channels and receptors, and as such are of significant interest to the pharmaceutical and biotech industries as both therapeutic leads and pharmacological tools. Their progression as clinical candidates, however, faces many of the challenges that are common to peptide drugs generally. Areas covered: The attributes of peptide toxins as therapeutic leads are outlined, as well as some of the limiting factors that have hampered the clinical development of many promising candidates. Strategies to overcome or circumvent these limitations are described, and their applications to peptide toxins from cone snails, sea anemones and scorpions are exemplified. Expert opinion: Peptide toxins have exceeded their promise as valuable pharmacological tools but have yet to yield the anticipated bounty of therapeutic leads. As the number of new peptides identified in venom transcriptomes and proteomes expands rapidly, screening approaches that capture those with genuine therapeutic potential are required, along with methods for enhancing the stability, pharmacokinetics and pharmacodynamics of these peptides.

KW - Cone snail

KW - cyclisation

KW - delivery

KW - disulfide

KW - PEGylation

KW - pharmacodynamics

KW - pharmacokinetics

KW - proteolysis

KW - scorpion

KW - sea anemone

UR - http://www.scopus.com/inward/record.url?scp=85019190925&partnerID=8YFLogxK

U2 - 10.1080/17460441.2017.1317243

DO - 10.1080/17460441.2017.1317243

M3 - Review Article

VL - 12

SP - 611

EP - 623

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 6

ER -